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Introduction
Psoriasis is a common, chronic, inflammatory skin condition affecting approximately 2% of the Caucasian population, with a highly variable clinical presentation and a significant long-term psychological and societal impact 1 . Current putative immunopathogenesis of psoriasis involves the dysregulation of cutaneous innate and adaptive immune responses, with T-cells having a primary role in the initiation and maintenance of the inflammatory process.
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This article is protected by copyright. All rights reserved. Henseler and Christophers (1985) described two distinct subtypes of chronic plaque psoriasis; early onset psoriasis (EOP), which presents before 40 years of age and accounts for 75% of patients and late onset psoriasis (LOP) which first presents after the age of 40 years (25% of patients). Patients with EOP were reported as more likely than those with LOP to: suffer from severe psoriasis; require systemic treatment;
have a family history of the disease and; be positive for the HLA-Cw*06:02 allele 2, 3 . Certain clinical phenotypes, such as guttate and erythrodermic psoriasis, are more frequent in EOP, whilst LOP is more likely to be limited to the scalp and nails 4, 5 . Our group has demonstrated that EOP and LOP have distinct genetic and immunopathogenic characteristics. We showed that only LOP is specifically associated with distinct polymorphisms at the interleukin (IL)-1B gene 6 , and also showed an impairment of epidermal Langerhans' cells (LCs) mobilization in response to IL-1β in the uninvolved skin of EOP but not LOP 7 .
Despite the above, the distinctions between EOP and LOP have not been fully delineated. We carried out a comprehensive analysis of immunohistologic, demographic, phenotypic and psychosocial parameters in EOP and LOP patients.
Materials and Methods
The studies were conducted at Salford Royal NHS Foundation Trust (SRFT), Manchester, UK, between 2010 and 2012. All contemporary patients provided informed consent and completed a detailed questionnaire covering key demographic and medical history, with a physical examination and full skin assessment performed by the study physician (ET).
Patients were included in the immunocytochemical study if they were Caucasian aged at least 50 years;
had a diagnosis of plaque psoriasis by a consultant dermatologist or GP for at least six months; had psoriasis on unexposed skin to the sun; and agreed to have an appropriate drug wash out period if they were on phototherapy, topical treatments or systemic therapy (2 weeks for topical treatments, 4 weeks for systemic therapies and phototherapy, 12 weeks for biological agents). The exclusion criteria included patients who had received lithium, anti-malarials, intramuscular gold within four weeks of the study visit;
diagnosed with HIV, hepatitis B or hepatitis C; had uncontrolled comorbid disease; had other
Accepted Article
This article is protected by copyright. All rights reserved.
inflammatory skin conditions; unwilling to undergo injection of local anaesthetic; participating in other studies using investigational agents or procedures; or donating a skin sample which is positive to Periodic acid Schiff (PAS) staining. Patients who developed psoriasis before age 40y were classified as EOP, whilst those whose psoriasis occurred after age 50y were included in the LOP group.
Each volunteer provided four, 6mm, skin biopsies (2,PP; 2,PN), taken from sun-protected buttock or hip under 1% lidocaine local anesthesia, were processed and stained with H&E. A Leica Bond-Max fully automated staining system (Leica Microsystems, UK) was used to stain the sections stained with T-cell markers, including CD1a, CD8 (DAKO Denmark), and CD3, CD4 (Leica Microsystems, UK). Six sections per biopsy were examined across the whole of the epidermis and dermis, per x200 magnification field.
Positive epidermal cells were presented in counts, whilst the dermal infiltrate was assessed using a 0-3 semi-quantitative scale depending on the severity of the inflammation from 0, none to 3, most severe.
Epidermal cell counts and epidermal CD4+/CD8+ ratio were presented as mean values ± SD and comparison between groups was carried out with independent samples t-test. The second level of analysis accounted for a priori potential confounding variables; including gender, disease duration, PASI and clinical phenotype; using a linear regression model. Dermal cell counts were presented as frequencies and compared for trends using chi square.
The clinical study was an observational cross-sectional study with contemporary and retrospective patients. Patients were included in the contemporary group if they were aged 18 years or above; had a diagnosis of psoriasis by a consultant dermatologist or GP; and had their first sign or symptom of psoriasis ≤ 12 months before diagnosis. The retrospective group comprised of patients with psoriasis who have attended the weekly psoriasis clinic between the years of 2005-2010, at SRFT. Patients were categorised in two different groups (EOP and LOP) using the same criteria as the above study. A set of psychometric questionnaires, including HADS, PSWQ, BDI-II and DLQI, was completed by the patients in the contemporary group. Regarding PSWQ, a score between 45 and 55 was set as a reference of moderate raised anxiety (within variable clinical presentation), while a score of 65 and above was a definite diagnosis for generalised anxiety disorder (GAD). 8, 9 Accepted Article
Patients in the retrospective group represented newly referred patients to the Psoriasis clinic, at SRFT. A proforma similar to the study questionnaire of the contemporary group was completed for all the patients, including demographic, clinical information and DLQI.
Family history of psoriasis was assessed in two different ways in the contemporary group: a) patients were asked whether they had a positive family of psoriasis in their 1st (parents, siblings and offspring) or 2nd degree (aunts, uncles, grandparents, grandchildren, nieces, nephews, or half-sibling) relatives. This information was extracted from the proformas for the retrospective group; however detailed information regarding the age of onset of the family members was not available in this data.
The assessment of clinical severity was made using the PASI. Clinical phenotype was defined by the following criteria in the contemporary group only: small thin plaques defined by plaque size ≤ 3cm, induration ≤0.75mm; small thick plaques defined by plaque size ≤ 3cm and induration > 0.75mm; large thin plaques by plaque size > 3cm and induration ≤0.75mm; large thick plaques by plaque size > 3cm and induration > 0.75mm. Continuous numerical variables were presented as mean values ± SD. Chi-square (x2) and Fischer's exact test were used to detect trends between categorical variables and independent samples; independent samples t-test was used to identify any significant differences in the means of continuous numerical data. Binary logistic regression was employed to control for a priori potential confounders and detect risk factors. As by definition all LOP patients were over 50 years old, analysis on a restricted cohort comparing patients over 50 years old in the EOP group against the LOP group was performed for associated comorbidities and psychosocial morbidity, in order to age-match the two groups. 
Results

Immunocytochemistry
The p=0.067). There were no observed differences between epidermis or dermis of uninvolved skin (PN) in EOP and LOP.
Clinical characteristics
The clinical study recruited 340 psoriasis patients (108 recruited at time of consent and 232 retrospectively), 278 EOP (mean age of onset of 20.6±9.9 years), and 62 LOP (mean age of onset of 55.4±7 years). Other demographic data are presented in table 1. The vast majority of subjects (96%) were Caucasian. There was no statistical difference in clinical severity or impact on quality of life between
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This article is protected by copyright. All rights reserved. Table 2 ). 12 EOP and 3 LOP patients had an affected mother with psoriasis, while 10 EOP and 2 LOP patients had an affected father, and the gender of affected parents was not associated with the type of psoriasis of the subjects (p=0.65).
In the clinical study, chronic plaque psoriasis was the most prevalent phenotype in both groups (86.7%, EOP; 88.1%, LOP; 
Associated comorbidities
Psoriatic arthritis occurred equally in both groups (25.3%, EOP; 23% LOP 
Psychological morbidity
Patients from both groups had a similar Dermatology Life Quality Index score (DLQI); mean DLQI for EOP 7.4±7.1; LOP, 7.8±7.1; p=0.7). In the contemporary group data (n=106), patients with LOP (n=31) 
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14) were asked to complete a Beck Depression Inventory-II (BDI-II), which showed no significant difference between groups (LOP 14±12; EOP 13 ±11; p=0.67).
Discussion
Immuno-immunocytochemical findings
We have demonstrated that there are distinct immunoimmunocytochemical differences between the 
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understanding that MHC class I is more likely to be linked to the function of CD8 T-cells than to CD4 Tcells 10 .
Clinical findings
In line with previous studies 3, 4, 11, 12 , we confirmed that EOP is a familial form of psoriasis; 62% of EOP patients had family history of psoriasis versus 35.6% of LOP subjects. Having an affected EOP parent was strongly associated with having EOP. This is the first study to detect the association between the age of onset of affected parents and EOP/LOP status in their offspring, and further supports the notion that the age of onset of psoriasis has a strong genetic background.
We found that small thick plaque, guttate, pustular and erythrodermic psoriasis were confined to EOP patients. This is partially congruent with previous research that demonstrated significant associations of EOP with guttate and eruptive psoriasis 5, 13 . It is important to note, however, that the sample size of the EOP group is more than four times the size of the LOP group. There is the possibility that these findings could be down to sample size and chance rather than representing a genuine association. Thus, larger studies are needed to interrogate these findings. Nail involvement was present in 88.9% of patients.
Contrary to other reports which connect nail psoriasis to either EOP 11 or LOP 14 , both groups had similar occurrence of nail changes.
In line with recent reports 15, 16 , EOP patients were more likely to be receiving biologic therapies, whilst LOP patients were more likely to be treated with phototherapy. Our observation that LOP patients had a higher prevalence of thin-plaque psoriasis (either small or large plaque) could act as a source of channelling bias towards phototherapy in this subset as this has form has been shown to be more responsive to phototherapy 17, 18 .
Our study is the first to extensively explore links between psoriasis comorbidities and the two subtypes of psoriasis. We showed that psoriatic arthritis occurred equally in both disease subsets. In keeping with other research groups, we also found an association of T2DM with LOP after accounting for relevant
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potential confounders, including history of ischaemic heart disease, hypertension, dyslipidaemia, central obesity, disease duration and disease severity 19, 20 . We demonstrated that LOP patients were approximately 2.5 times more likely to have T2DM compared to EOP patients (OR 2.6, 95% CI 1.001-6.538).
To our knowledge, this is the first study to show an association between AIT and LOP. We showed that LOP patients were 5 times more likely to have AIT than EOP patients. It is unclear from the literature regarding the overall association of AIT with psoriasis -one study found a higher prevalence of AIT in
PsA patients as compared to controls 21 , while another study looking at psoriasis patients without PsA did not find an association of AIT with psoriasis 22 . It should be noted that the mean age of the patients with psoriasis in the latter study was 40.5, and therefore this study is unlikely to have included many patients with LOP.
There is strong evidence that psoriasis has a profound psychosocial impact on the daily life of patients [23] [24] [25] . It is also well established that anxiety increases with age in psoriasis patients 26 . After controlling for age by stratification, we showed that for patients aged 50 years or above, LOP patients were clinically more anxious than those with EOP, which is contrary to other reports 27, 28 .
Limitations to the histologic study include a gender imbalance between study groups, with 80% of EOP patients being male, whereas for the LOP group the male to female ratio was equal. Unsurprisingly, LOP patients had a shorter duration of disease compared to EOP (supplementary data, Table 4 ), and therefore disease duration cannot be ruled out as a confounder or an intermediate variable accounting for some of our findings. Our study population consisted mainly of Caucasians, hence limiting generalisability to other psoriasis populations. Certain data from the clinical study could be influenced by recall bias. There was also limited information on the HLA-Cw*0602 profile of the study patients; thus it remains for a more thorough assessment to be performed of any association between epidermal T-cell phenotypes and HLA status. The sample size for the immunocytochemical study was small and this is reflected in the wide 95%
confidence intervals reported.
Summary
Our results suggest that an infiltration of epidermal CD4 + T-cells and the consequent increase in the ratio of epidermal CD4 + /CD8 + in the LOP group is a differentiating factor between the two subtypes of psoriasis. There were differences between the demographic and clinical features of EOP and LOP, with a stronger association with family history of psoriasis found in EOP patients, and higher levels of anxiety and stronger associations with T2DM and AIT found in LOP patients. The data add further weight to the hypothesis that EOP and LOP are two distinct subtypes of psoriasis with a difference in immunocytochemical, immunological and demographic background; heritability; clinical phenotypical features and; the experience of anxiety in the sub-group older than 50 years. This in turn should be taken into account when managing the two conditions.
Figure legends
Figure 1 Box-plot comparing mean epidermal CD4 + , CD8 + , CD3 + and CD1a + cell counts in involved skin of early-onset psoriasis (EOP; n=17) and late onset psoriasis (LOP;n=14) patients, presenting the median and the interquartile range. P= p-value for t-test comparing difference in the mean values. There is an increased CD4:CD8 ratio in the PP epidermis of LOP compared to EOP.
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This article is protected by copyright. All rights reserved. Table 3 Distribution of clinical phenotypes of psoriasis between early onset (EOP) and late onset psoriasis (LOP) groups. To detect significant differences, when the expected count of cells was 0, the test of independent proportions was used. When the expected count of cells was >0 but <5, the Fisher's exact test was used. *analysis only includes patient from contemporary group (n=84). 
